Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Cell reports · 2021
    DSDespina Siolas
    PMID: 34433022PMCID: PMC8687588DOIFirst author75 citations
  2. 2
    JCO precision oncology · 2026
    DSDespina Siolas
    PMID: 41931740PMCID: PMC13064832DOISenior author1 citations
  3. 3
    Journal of pancreatology · 2020
    DSDespina Siolas
    PMID: 33133736PMCID: PMC7595263DOIFirst author7 citations

Publications

21 publications

Funding

5 grantsView NIH portfolio on RePORTER ↗

Active

3 grants
  • Co-I
    PICI Grant and Main Collaboration Agreement with Multiple Subprojects
    Parker Institute for Cancer Immunotherapy · 2024–2028
    PICI 235170-01
  • PI
    Defining the impact of Kras mutational heterogeneity on the tumor microenvironment in pancreatic cancer
    Project Purple INC · 2026–2027
    PP 255004-01
  • PI
    Defining the impact of Kras mutational heterogeneity on the tumor microenvironment in pancreatic cancer
    U.S. Department of Defense · 2023–2026
    HT9425-23-1-0731
Completed grants (2)
  • PI
    Defining the impact of Kras heterogeneity on the tumor microenvironment
    National Pancreas Foundation · 2023–2024
    NPF 230215-01
  • PI
    Investigating the non-cell autonomous immune effects of mutant p53 in pancreatic cancer
    National Cancer Institute · 2021–2024
    K08CA241341-03

Clinical research

4 studies

Active

1 study
  • PI
    Defining the Impact of KRAS Heterogeneity on the Tumor Microenvironment in Pancreatic Cancer
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2023)
Completed & closed trials (3)
  • PI
    Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)
    PHASE1 · National Cancer Institute · CLOSED TO ACCRUAL (as of 2026)
    Advanced Breast Carcinoma; Advanced Colon Carcinoma; Advanced Colorectal Carcinoma; Advanced Endometrial Carcinoma; Advanced Gastric Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Advanced Malignant Solid Neoplasm; Advanced Salivary Gland Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; HER2-Positive Breast Carcinoma; Malignant Hepatobiliary Neoplasm; Metastatic Breast Carcinoma; Metastatic Colon Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Salivary Gland Carcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Major Salivary Gland Cancer AJCC v8; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Major Salivary Gland Cancer AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Unresectable Breast Carcinoma; Unresectable Colon Carcinoma; Unresectable Colorectal Carcinoma; Unresectable Endometrial Carcinoma; Unresectable Gastric Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Salivary Gland Carcinoma
    NCT04704661
  • PI
    Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
    PHASE2 · Leap Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2025)
    Colorectal Cancer; Colorectal Adenocarcinoma; Colo-rectal Cancer; Colorectal Cancer Metastatic
    NCT05480306
  • PI
    A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
    PHASE1; PHASE2 · Verastem · CLOSED TO ACCRUAL (as of 2025)
    KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neoplasm of Pancreas
    NCT05669482

News mentions

1 mentionView all WCM news ↗

Mentoring

2 mentees

External relationships

Advisory/Scientific Board Member

Bristol-Myers Squibb Foundation INC · Natera, Inc.

Other

Zephyr AI, Inc.